Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naïve mice and those with preexisting immunity

Clinical and Vaccine Immunology

Volumn 19, Issue 1, 2012, Pages 84-95

  Choi, Jin Huk ^a   Dekker, Joe ^a   Schafer, Stephen C ^a   John, Jobby ^a   Whitfill, Craig E ^b   Petty, Christopher S ^b   Haddad, Eid E ^b   Croyle, Maria A ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Immunobiosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADENOVIRUS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOCYTE COUNT; TRANSGENE; VIRUS PARTICLE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIBODIES; ANTIBODIES, VIRAL; ANTIGEN-ANTIBODY COMPLEX; B-LYMPHOCYTES; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALE; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VACCINES;

EID: 84862917929     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05319-11     Document Type: Article

References (60)

1. Appledorn DM, et al. 2008. Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther. 15:1606-1617.
2. Appledorn DM, et al. 2008. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J. Immunol. 181:2134-2144.
3. Baker AH, McVey JH, Waddington SN, Di Paolo NC, Shayakhmetov DM. 2007. The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol. Ther. 15:1410-1416. (Pubitemid 47099297)
4. Benlahrech A, et al. 2009. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl. Acad. Sci. U. S. A. 106:19940-19945.
5. Boquet MP, Wonganan P, Dekker JD, Croyle MA. 2008. Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism. J. Pharmacol. Toxicol. Methods 58:222-232.
6. Boyer J, et al. 2010. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into the adenovirus capsid. Hum. Gene Ther. 21:891-901.
7. Callahan SM, Boquet MP, Ming X, Brunner LJ, Croyle MA. 2006. Impact of transgene expression on drug metabolism following systemic adenoviral vector administration. J. Gene Med. 8:566-576. (Pubitemid 43827250)
8. Callahan SM, et al. 2008. Controlled inactivation of recombinant viruses with vitamin B2. J. Virol. Methods 148:132-145.
9. Cheng C, et al. 2010. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J. Virol. 84:630-638.
10. Chirmule N, et al. 1999. Immune responses to adenovirus and adenoassociated virus in humans. Gene Ther. 6:1574-1583. (Pubitemid 29465516)
11. Croyle MA, Chirmule N, Zhang Y, Wilson JM. 2002. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 13:1887-1900. (Pubitemid 35292683)
12. Croyle MA, Chirmule N, Zhang Y, Wilson JM. 2001. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75:4792-4801. (Pubitemid 32381522)
13. Croyle MA, Roessler BJ, Davidson BL, Hilfinger JM, Amidon GL. 1998. Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharm. Dev. Technol. 3:373-383. (Pubitemid 28410365)
14. Deckert PM. 2009. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr. Drug Targets 10:158-175.
15. Descamps D, Benihoud K. 2009. Two key challenges for effective adenovirus-mediated liver gene therapy: innate immune responses and hepatocyte-specific transduction. Curr. Gene Ther. 9:115-127.
16. Dharmapuri S, Peruzzi D, Aurisicchio L. 2009. Engineered adenovirus serotypes for overcoming anti-vector immunity. Expert Opin. Biol. Ther. 9:1279-1287.
17. Geisbert TW, et al. 2011. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol. 85:4222-4233.
18. Gosselin EJ, Bitsaktsis C, Li Y, Iglesias BV. 2009. Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens. Arch. Immunol. Ther. Exp. (Warsz.) 57:311-323.
19. Graham FL, van der Eb AJ. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467.
20. Hartman ZC, Appledorn DM, Amalfitano A. 2008. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 132:1-14. (Pubitemid 351232078)
21. Jager L, Ehrhardt A. 2007. Emerging adenoviral vectors for stable correction of genetic disorders. Curr. Gene Ther. 7:272-283. (Pubitemid 47240700)
22. Jooss K, Ertl HC, Wilson JM. 1998. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J. Virol. 72:2945-2954. (Pubitemid 28175532)
23. Kreppel F, Kochanek S. 2008. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther. 16:16-29.
24. Lasaro MO, Ertl HC. 2009. New insights on adenovirus as vaccine vectors. Mol. Ther. 17:1333-1339.
25. Leopold PL, Wendland RL, Vincent T, Crystal RG. 2006. Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway. J. Virol. 80:10237-10247. (Pubitemid 44522617)
26. Lieber A, et al. 1997. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71:8798-8807. (Pubitemid 27446464)
27. Liniger M, Zuniga A, Naim HY. 2007. Use of viral vectors for the development of vaccines. Expert Rev. Vaccines 6:255-266. (Pubitemid 46613525)
28. Liu MA. 2010. Immunologic basis of vaccine vectors. Immunity 33:504-515.
29. Lux A, Nimmerjahn F. 2012. Impact of differential glycosylation on IgG activity. Adv. Exp. Med. Biol. 780:113-124.
30. Manickan E, et al. 2006. Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol. Ther. 13:108-117. (Pubitemid 41763488)
31. Muruve DA, et al. 2008. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452: 103-108.
32. O'Brien KL, et al. 2009. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat. Med. 15:873-875.
33. Olivier V, Duval JL, Hindié M, Pouletaut P, Nagel MD. 2003. Comparative particle-induced cytotoxicity toward macrophages and fibroblasts. Cell Biol. Toxicol. 19:145-159. (Pubitemid 36975595)
34. Overwijk WW, Surman DR, Tsung K, Restifo NP. 1997. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods 12:117-123. (Pubitemid 27241368)
35. Parker AL, et al. 2009. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J. Virol. 83:479-483.
36. Perreau M, Pantaleo G, Kremer EJ. 2008. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J. Exp. Med. 205:2717-2725.
37. Pichla-Gollon SL, et al. 2009. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J. Virol. 83:5567-5573.
38. Pilankatta R, Chawla T, Khanna N, Swaminathan S. 2010. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J. Med. Virol. 82:407-414.
39. Pleass RJ. 2009. Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunol. 31:529-538.
40. Quimby FW. 1999. The mouse, p 3-33. In Loeb WF, Quimby FW (ed), The clinical chemistry of laboratory animals, second ed. Taylor and Francis, Philadelphia, PA.
41. Raper SE, et al. 2003. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80:148-158. (Pubitemid 37272241)
42. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
43. Sakurai F. 2008. Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35. Biol. Pharm. Bull. 31:1819-1825.
44. Sakurai F, Kawabata K, Mizuguchi H. 2007. Adenovirus vectors composed of subgroup B adenoviruses. Curr. Gene Ther. 7:229-238. (Pubitemid 47232955)
45. Schroeder HW, Cavacini L. 2010. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125:S41-S52.
46. Seiler MP, Cerullo V, Lee B. 2007. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr. Gene Ther. 7:297-305. (Pubitemid 47595772)
47. Seregin SS, Amalfitano A. 2009. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin. Biol. Ther. 9:1521-1531.
48. Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT. 1994. Macrophage/particle interactions: effect of size, composition and surface area. J. Biomed. Mater. Res. 28:81-90. (Pubitemid 24006480)
49. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. 2005. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79:7478-7491. (Pubitemid 40756784)
50. Sumida SM, et al. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174:7179-7185. (Pubitemid 40705685)
51. Thacker EE, Timares L, Matthews QL. 2009. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev. Vaccines 8:761-777.
52. Thorner AR, et al. 2006. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J. Clin. Microbiol. 44:3781-3783. (Pubitemid 46768807)
53. Tollefson AE, Kuppuswamy M, Shashkova EV, Doronin K, Wold WS. 2007. Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol. Med. 130:223-235.
54. Worgall S, et al. 2007. Protective immunity to Pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J. Virol. 81:13801-13808. (Pubitemid 350247873)
55. Xu Z, Tian J, Smith JS, Byrnes AP. 2008. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J. Virol. 82:11705-11713.
56. Yang TC, et al. 2007. T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev. Vaccines 6:347-356.
57. Yang Y, Wilson JM. 1995. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLAs in vivo. J. Immunol. 155:2564-2570.
58. Yang Y, Jooss K, Su Q, Ertl HC, Wilson JM. 1996. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected adenovirus hepatocytes in vivo. Gene Ther. 3:137-144. (Pubitemid 26117423)
59. Zaiss AK, Machado HB, Herschman HR. 2009. The influence of innate and pre-existing immunity on adenovirus therapy. J. Cell. Biochem. 108:778-790.
60. Zhu J, Huang X, Yang Y. 2007. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol. 81:3170-3180. (Pubitemid 46456626)